DarioHealth (DRIO) EBITDA (2012 - 2026)

DarioHealth (DRIO) has reported EBITDA for 15 consecutive years, with -$6.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 29.58% year-over-year to -$6.5 million; the trailing twelve-month figure through Jun 2026 stood at -$31.8 million (up 24.75% YoY), and the FY2025 full-year result was -$36.7 million, up 36.52% from the prior year.
• EBITDA rose to -$6.5 million in Q2 2026 per DRIO's latest filing, from -$7.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$6.5 million in Q2 2026 and bottomed at -$17.9 million in Q1 2024.
• Historically, EBITDA has averaged -$12.3 million across 5 years, with a median of -$12.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA jumped 58.41% in 2022, then slumped 57.77% in 2023.
• Over 5 years, EBITDA stood at -$9.0 million in 2022, then plunged by 57.77% to -$14.2 million in 2023, then advanced by 17.92% to -$11.7 million in 2024, then climbed by 26.62% to -$8.6 million in 2025, then advanced by 24.33% to -$6.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$6.5 million, -$7.3 million, and -$8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.